FDA Inspection 982641 — Wuhan Biocause Pharmaceutical Development Co., Ltd.
The FDA completed an inspection of Wuhan Biocause Pharmaceutical Development Co., Ltd. on Jul 22, 2016 in Wuhan. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Jul 22, 2016
- Fiscal Year
- 2016
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Wuhan (China)